表紙
市場調查報告書

肌肉萎縮性側索硬化症 (ALS) 治療藥:機會評估,流行病學研究,市場動態,開發平台分析

Amyotrophic Lateral Sclerosis Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H2 2019

出版商 GervanoRA Data Services LLP 商品編碼 913758
出版日期 內容資訊 英文 155 Pages
訂單完成後即時交付
價格
肌肉萎縮性側索硬化症 (ALS) 治療藥:機會評估,流行病學研究,市場動態,開發平台分析 Amyotrophic Lateral Sclerosis Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H2 2019
出版日期: 2019年10月10日內容資訊: 英文 155 Pages
簡介

本報告提供全球肌肉萎縮性側索硬化症 (ALS) 治療藥市場相關調查分析,現在、未來的機會為焦點,市場價值,專利分析,市場佔有率等相關的系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 疾病概要

  • 疾病定義與症狀
  • 病因與分類
  • 疾病診斷
  • 治療流程和指南
  • 流行病學研究
  • 流行病學預測

第4章 市場動態

  • 交易 (M&A,聯盟)
  • 專利分析 (失效,學名藥)

第5章 開發平台分析

  • 開發平台分析:各開發階段
  • 開發平台分析:各地區
  • 開發平台分析:各給藥途徑
  • 開發平台分析:各藥物分類
  • 開發平台分析:各作用機制
  • 開發平台分析:各大學、機關

第6章 核准計劃的預測

第7章 臨床實驗的摘要

  • 分析:各臨床實驗結果
  • 進行中的臨床實驗的摘要
  • 計劃中臨床實驗的摘要
  • 最近完成的臨床實驗的摘要

第8章 中止的計劃

第9章 機會評估和競爭基準

第10章 現在、未來的競爭情形

  • 現有企業
  • 新興企業

第11章 簡稱

目錄
Product Code: GERPH520

GervanoRA's pipeline analysis and opportunity assessment report "Amyotrophic Lateral Sclerosis Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H2 2019" analyzed and assessed Amyotrophic Lateral Sclerosis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Amyotrophic Lateral Sclerosis industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Growth Opportunities in the report have been provided by performing a competitive and comparative analysis on the top 20 Emerging companies in the domain and hence deriving the key leader in the Amyotrophic Lateral Sclerosis Space.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast till 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2 KEY EVENTS IN THE COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

3. DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY STUDIES
    • 3.5.1. GLOBAL AND HISTORICAL TRENDS
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
  • 4.2. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

5. PIPELINE ANALYSIS

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE - REGISTRATION MOLECULES
    • 5.1.2. PHASE 3 MOLECULES
    • 5.1.3. PHASE 2 MOLECULES
    • 5.1.4. PHASE 1 MOLECULES
    • 5.1.5. PRECLINICAL MOLECULES
    • 5.1.6. EARLY R&D MOLECULES
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    • 5.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE MOLECULES BY UNIVERSITY AND INSTITUTES - IN LICENSING AND OUT LICENSING OPPORTUNITIES

6. ESTIMATED APPROVAL TIMELINES

  • 6.1. METHODOLOGY
  • 6.2. ESTIMATED APPROVAL TIMELINES US & EX-US

7. CLINICAL TRIALS SUMMARY

  • 7.1. ANALYSIS BY CLINICAL TRIAL RESULTS
    • 7.1.1. KEY PHASE 3 CLINICAL TRIAL RESULTS
    • 7.1.2. KEY PHASE 2 CLINICAL TRIAL RESULTS
  • 7.2. ONGOING CLINICAL TRIALS SUMMARY
    • 7.2.1. PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    • 7.2.2. PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    • 7.2.3. PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
  • 7.3. PLANNED CLINICAL TRIALS SUMMARY
    • 7.3.1. PLANNED PHASE 3 CLINICAL TRIALS
    • 7.3.2. PLANNED PHASE 2 CLINICAL TRIALS
    • 7.3.3. PLANNED PHASE 1 CLINICAL TRIALS
  • 7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    • 7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
    • 7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
    • 7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS

8. WITHDRAWN AND TERMINATED PROJECTS

  • 8.1. WITHDRAWN CLINICAL TRIALS
  • 8.2. TERMINATED CLINICAL TRIALS

9. OPPORTUNITY ASSESSMENT AND COMPETITIVE BENCH-MARKING

  • 9.1. EXTERNAL DEPENDENCIES
  • 9.2. PIPELINE PORTFOLIO
  • 9.3. EXPECTED MARKET ENTRIES
  • 9.4. PATENTS AND EXCLUSIVITY
  • 9.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
  • 9.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 9.7. COMPANY DEVELOPMENTS

10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 10.1. ESTABLISHED COMPANIES
    • 10.1.1. KEY COMPANY PROFILES AND SWOT ANALYSIS
  • 10.2. EMERGING COMPANIES
    • 10.2.1. KEY EMERGING COMPANY PROFILES

11. ABBREVIATIONS

LIST OF TABLES:

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: TOP 10 DEALS IN THE AMYOTROPHIC LATERAL SCLEROSIS RANKED BY DEAL AMOUNT
  • TABLE 03: MAJOR COLLABORATIONS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • TABLE 04: MAJOR MERGERS AND ACQUISITIONS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • TABLE 05: MAJOR FINANCING DEALS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • TABLE 06: MAJOR LICENSING DEALS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • TABLE 07: PATENT PORTFOLIO OF BRAINSTORM CELL THERAPEUTICS
  • TABLE 08: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
  • TABLE 09: AMYOTROPHIC LATERAL SCLEROSIS PRE - REGISTRATION CANDIDATES
  • TABLE 10: PHASE 3 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 11: PHASE 2 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 12: PHASE 1 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 13: PRECLINICAL MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 14: EARLY R&D MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 15: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE ANALYSIS BY ORAL ROA
  • TABLE 16: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE ANALYSIS BY INJECTABLE AS ROA
  • TABLE 17: CELL THERAPIES AND GENE THERAPIES UNDER DEVELOPMENT FOR ALS
  • TABLE 18: UNIVERSITY'S PIPELINE MOLECULES FOR ALS
  • TABLE 19: ESTIMATED APPROVAL TIMELINES OF ALS PIPELINE DRUGS
  • TABLE 20: MASITINIB PHASE 2/3 CLINICAL TRIAL STUDY DESIGN
  • TABLE 21: MASITINIB PHASE 2/3 PRIMARY END POINT
  • TABLE 22: MASITINIB PHASE 2/3 SECONDARY END POINT PFS
  • TABLE 23: MASITINIB PHASE 2/3 SECONDARY END POINT FVC
  • TABLE 24: MASITINIB PHASE 2/3 SECONDARY END POINT ALSAQ-40 SCORE
  • TABLE 25: REFALS CLINICAL TRIAL STUDY DESIGN
  • TABLE 26: PHASE 2 STUDY DESIGN FOR ALS
  • TABLE 27: FORTITUDE-ALS PHASE 2A STUDY DESIGN
  • TABLE 28: PHASE 3 ONGOING CLINICAL TRIALS
  • TABLE 29: PHASE 2 ONGOING CLINICAL TRIALS
  • TABLE 30: PHASE 1 ONGOING CLINICAL TRIALS
  • TABLE 31: PLANNED PHASE 3 CLINICAL TRIALS FOR ALS
  • TABLE 32: PLANNED PHASE 1 CLINICAL TRIALS FOR ALS
  • TABLE 33: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS FOR ALS
  • TABLE 34: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS FOR ALS
  • TABLE 35: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS FOR ALS
  • TABLE 36: WITHDRAWN CLINICAL TRIALS FOR ALS
  • TABLE 37: TERMINATED CLINICAL TRIALS FOR ALS
  • TABLE 38: EXTERNAL FUNDING RECEIVED BY TOP EMERGING COMPANIES (RANKED LEAST TO MAXIMUM)
  • TABLE 39: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES (ALS)
  • TABLE 40: MAJOR REVENUE GENERATING DRUGS
  • TABLE 41: PIPELINE DRUGS, IMMUNO - INFLAMMATION AREA
  • TABLE 42: PIPELINE DRUGS, DIABETES AND KIDNEY AREA
  • TABLE 43: PIPELINE DRUGS, CNS AREA
  • TABLE 44: RECENT DRUG FILINGS AND APPROVALS RECEIVED BY MITSUBISHI TANABE PHARMA
  • TABLE 45: RECENT R&D ACTIVITIES OF MITSUBISHI TANABE PHARMA
  • TABLE 46: RECENT DEALS ACTIVITIES OF MITSUBISHI TANABE PHARMA
  • TABLE 47: RECENT DEVELOPMENTS OF MITSUBISHI TANABE PHARMA
  • TABLE 48: R&D ACTIVITIES AND RECENT DEVELOPMENTS OF ITF PHARMA
  • TABLE 49: BIOHAVEN'S PIPELINE ASSETS
  • TABLE 50: MAJOR PATENTS PROTECTING RIMEGEPANT AND BHV-3500
  • TABLE 51: RECENT R&D ACTIVITIES AND DEVELOPMENTS OF BIOHAVEN
  • TABLE 52: ANTICIPATED NEAR FUTURE MILESTONES OF BIOHAVEN
  • TABLE 53: BRAINSTORM CELL THERAPEUTICS' PIPELINE ASSETS
  • TABLE 54: KEY INTELLECTUAL PROPERTY PORTFOLIO OF BRAINSTORM CELL THERAPEUTICS
  • TABLE 55: RECENT DEVELOPMENTS AND R&D ACTIVITIES OF BRAINSTORM CELL THERAPEUTICS
  • TABLE 56: ANTICIPATED NEAR FUTURE MILESTONES OF BRAINSTORM CELL THERAPEUTICS
  • TABLE 57: CYTOKINETICS PIPELINE DRUGS
  • TABLE 58: RECENT R&D ACTIVITIES AND DEVELOPMENTS OF CYTOKINETICS
  • TABLE 59: NEURALSTEM'S PIPELINE DRUGS
  • TABLE 60: RECENT R&D ACTIVITIES AND DEVELOPMENTS OF NEURALSTEM
  • TABLE 61: MEDICINOVA'S PIPELINE ASSETS
  • TABLE 62: PATENTS COVERING MN-166(IBUDILAST)
  • TABLE 63: PATENTS COVERING MN-001 (TIPELUKAST)
  • TABLE 64: RECENT R&D ACTIVITIES AND DEVELOPMENTS OF MEDICINOVA
  • TABLE 65: PHARNEXT PIPELINE DRUGS
  • TABLE 66: RECENT R&D ACTIVITIES AND DEVELOPMENTS OF PHARNEXT
  • TABLE 67: PHARNEXT MILESTONES
  • TABLE 68: GENERVON BIOPHARMACEUTICALS PIPELINE DRUGS
  • TABLE 69: RECENT R&D ACTIVITIES AND DEVELOPMENTS OF GENERVON BIOPHARMACEUTICALS, LLC
  • TABLE 70: KADIMASTEM'S STEM CELL THERAPIES IN PIPELINE
  • TABLE 71: RECENT R&D ACTIVITIES AND DEVELOPMENTS OF KADIMASTEM
  • TABLE 72: KADIMASTEM'S MILESTONES

LIST OF FIGURES:

  • FIGURE 01: KEY EVENTS IN ALS AREA, 2015-2035
  • FIGURE 02: GENETICS OF ALS
  • FIGURE 03: ALS EPIDEMIOLOGY FORECAST (2019-2025), US
  • FIGURE 04: ALS EPIDEMIOLOGY FORECAST (2019-2025), EUROPE
  • FIGURE 05: AMYOTROPHIC LATERAL SCLEROSIS DEALS, BY DEAL TYPE
  • FIGURE 06: AMYOTROPHIC LATERAL SCLEROSIS DEALS SCENARIO, YEAR V/S DEAL AMOUNT ($M)
  • FIGURE 07: AMYOTROPHIC LATERAL SCLEROSIS DEAL AMOUNT SHARE BY DEAL TYPE
  • FIGURE 08: YEAR WISE SPLIT-UP OF COLLABORATIONS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • FIGURE 09: PHARMACEUTICAL COMPANIES INVOLVED IN MORE THAN A SINGLE DEAL IN ALS AREA
  • FIGURE 10: NUMBER OF AMYOTROPHIC LATERAL SCLEROSIS DEALS, YEAR BY YEAR
  • FIGURE 11: INCREASING COLLABORATION/PARTNERING DEALS
  • FIGURE 12: COMPANIES FOUNDED BY AVALON AND GSK
  • FIGURE 13: PIPELINE MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS AREA, PERCENT SHARE
  • FIGURE 14: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE SPLIT BY GEOGRAPHY, NUMBER OF EXPECTED DRUG APPROVALS
  • FIGURE 15: AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 16: AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 17: ORALS BY HSD SPLIT-UP
  • FIGURE 18: INJECTABLES BY HSD SPLIT-UP
  • FIGURE 19: EXPECTED NUMBER OF KEY DRUG APPROVALS IN ALS, 2020- 2030
  • FIGURE 20: NUROWN V/S PLACEBO ALSFRS-R RESPONDER ANALYSIS B IN INTENT TO TREAT POPULATION UPTO 24 WEEKS
  • FIGURE 21: NUROWN V/S PLACEBO ALSFRS-R RESPONDER ANALYSIS IN INTENT TO TREAT POPULATION PER MONTH
  • FIGURE 22: NUROWN V/S PLACEBO ALSFRS-R RESPONDER ANALYSIS IN FASTER PROGRESSING SUBGRPOUP
  • FIGURE 23: PRIMARY EFFECT END POINT ANALYSIS (BASELINE CHANGE IN % PREDICTED SVC AT 12 WEEKS)
  • FIGURE 24: SECONDARY EFFECT END POINT ANALYSIS (BASELINE CHANGE IN ALSFRS-R GROSS MOTOR DOMAIN)
  • FIGURE 25: RECENTLY COMPLETED CLINICAL TRIALS, 2014 - 2019
  • FIGURE 26: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS, 2014-2018
  • FIGURE 27: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS, 2014-2019
  • FIGURE 28: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS, 2017-2019
  • FIGURE 29: INTERNAL INVESTMENT OF THE TOP EMERGING COMPANIES, $ MILLION
  • FIGURE 30: PIPELINE PORTFOLIO
  • FIGURE 31: EXPECTED MARKET ENTRY
  • FIGURE 32: EXPECTED MARKET ENTRY (ALS)
  • FIGURE 33: PATENT PORTFOLIO COMPARISON OF TOP EMERGING COMPANIES
  • FIGURE 34: TIMELINE OF PATENT EXPIRIES
  • FIGURE 35: TIMELINE OF PATENT EXPIRIES WRT ALS (GRANTED PATENTS)
  • FIGURE 36: RANKING OF TOP EMERGING COMPANIES BASED ON PARTNERING ACTIVITIES
  • FIGURE 37: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • FIGURE 38: KEY TITLES AND AWARDS ACHIEVED BY THE EMERGING COMPANIES
  • FIGURE 39: MITSUBISHI TANABE PHARMA, ANNUAL SALES V/S R&D EXPENSES
  • FIGURE 40: MITSUBISHI TANABE PHARMA, FY 2018 ANNUAL REVENUE SPLIT
  • FIGURE 41: MITSUBISHI TANABE PHARMA, FY 2018 ANNUAL REVENUE SPLIT BY GEOGRAPHIES
  • FIGURE 42: TOTAL OPERATIONAL EXPENSES OF BIOHAVEN IN $THOUSAND
  • FIGURE 43: TOTAL R&D EXPENSE OF BIOHAVEN IN $MILLION
  • FIGURE 44: OPERATIONAL COSTS OF BRAINSTORM CELL THERAPEUTICS IN MILLIONS (2017 AND 2018)
  • FIGURE 45: RESEARCH AND DEVELOPMENT EXPENSE OF BRAINSTORM CELL THERAPEUTICS IN MILLIONS (2017 AND 2018)
  • FIGURE 46: TOTAL OPERATIONAL EXPENSES OF CYTOKINETICS (2015, 2016, 2017 AND 2018) IN THOUSAND ($)
  • FIGURE 47: RESEARCH AND DEVELOPMENT EXPENSE OF CYTOKINETICS IN MILLIONS (2016, 2017 AND 2018)
  • FIGURE 48: TOTAL OPERATIONAL EXPENSES OF NEURALSTEM (2016, 2017 AND 2018) ($M)
  • FIGURE 49: RESEARCH AND DEVELOPMENT EXPENSE OF NEURALSTEM IN MILLIONS (2016, 2017 AND 2018)
  • FIGURE 50: TOTAL OPERATIONAL EXPENSES OF MEDICINOVA (2014, 2015, 2016, 2017 AND 2018) IN THOUSAND ($)
  • FIGURE 51: TOTAL R&D EXPENSE OF MEDICINOVA (2016, 2017 AND 2018) IN THOUSANDS ($)